World Health Organization Sounds Concern Over Critical Lack of Weight-Loss Jabs

Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it issues its first guidance on the medications.

Given more than one billion individuals worldwide now classified as obese, it is urging increased and just access to these injectable treatments.

Per projections, over two billion will be living with obesity by 2030 if no action is taken.

"The latest guidance acknowledges that excess weight is a lifelong illness that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to broad availability to the injections that can aid individuals in losing significant weight, says the organization.

Skinny Jab Supply Crisis

Despite the present most optimistic scenario, the production of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the WHO.

The recommendation encourages nations and manufacturers to widen access, through measures such as voluntary licensing.

A patent on the active ingredient – the primary component of a leading brand – is set to lapse in several countries in 2026.

How Obesity Injections Function

The injections replicate a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people consume fewer calories.

Patients typically start to lose weight within a few weeks of commencing the once-weekly jabs.

Evidence indicates patients may put most of the weight back on within a year of halting the drug, as their normal food cravings resume.

To be overweight or obese increases your chance for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and certain cancers.

Obesity impacts individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the health agency.